ABSTRACT
Introduction .................................................................................................................................... 878 History of Telemetry in Nonclinical Drug Safety Assessment ...................................................... 878 Physiologic Endpoints Available by Telemetry.............................................................................. 879
Cardiovascular System .............................................................................................................. 879 Respiratory System ................................................................................................................... 879 Central Nervous System ............................................................................................................880 Other Applications ....................................................................................................................880
Characteristics of Implantable Telemetry Systems ........................................................................ 881 Battery Technology ................................................................................................................... 881 Considerations for Product Reuse ............................................................................................. 882 Transmission Range and Tissue Penetration ............................................................................. 882 Single vs. Group (Social) Housing ............................................................................................ 883
